L3VLUP
ProSign in

PEN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PENJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PEN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterPENJNJ
Q3 202013 holders, $2.3bn30 holders, $26.2bn
Q4 202010 holders, $2.5bn32 holders, $26.6bn
Q1 202114 holders, $3.6bn31 holders, $25.3bn
Q2 202112 holders, $3.3bn37 holders, $25.6bn
Q3 202113 holders, $3.3bn40 holders, $24.1bn
Q4 202113 holders, $3.5bn33 holders, $25.2bn
Q1 20229 holders, $2.5bn35 holders, $28.2bn
Q2 20229 holders, $1.3bn33 holders, $26.9bn
Q3 202211 holders, $2.0bn36 holders, $25.4bn
Q4 202213 holders, $2.6bn35 holders, $27.6bn
Q1 20239 holders, $3.5bn42 holders, $24.5bn
Q2 202319 holders, $4.2bn38 holders, $25.0bn
Q3 202314 holders, $2.8bn37 holders, $18.9bn
Q4 202311 holders, $3.3bn31 holders, $19.0bn
Q1 202411 holders, $2.6bn32 holders, $19.7bn
Q2 202410 holders, $2.0bn35 holders, $20.4bn
Q3 202410 holders, $2.0bn28 holders, $22.3bn
Q4 202411 holders, $2.4bn37 holders, $20.4bn
Q1 202514 holders, $2.9bn32 holders, $20.5bn
Q2 202515 holders, $2.7bn31 holders, $18.4bn
Q3 202510 holders, $2.9bn32 holders, $23.7bn
Q4 202516 holders, $3.8bn29 holders, $27.8bn
Q1 202620 holders, $2.1bn34 holders, $35.6bn
Q2 202617 holders, $2.2bn33 holders, $39.1bn
PEN

Penumbra Inc

Holders
20
Reported value
$2.1bn
Buyers
23
Sellers
15

Breadth +8 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
34
Reported value
$35.6bn
Buyers
21
Sellers
18

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 41 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PEN (7)

Baillie Gifford & Co, Caxton Associates LLP, ExodusPoint Capital Management LP, Holocene Advisors LP, Moore Capital Management LP, Quantbot Technologies LP, Tudor Investment Corp

Only JNJ (21)

Acadian Asset Management LLC, AQR Capital Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Rokos Capital Management LLP, T. Rowe Price Associates Inc, Walleye Capital LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →